Cormorant Asset Management, LP Rubius Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$7.23 - $14.12 $3.55 Million - $6.94 Million	-491,700 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$7.85 - $15.75 $850,155 - $1.71 Million	-108,300 Reduced 18.05%	491,700 $3.86 Million
Q2 2019 Aug 14, 2019	SELL	$13.5 - $19.94 $675,000 - $997,000	-50,000 Reduced 7.69%	600,000 $9.44 Million
Q1 2019 May 15, 2019	BUY	$13.27 - $18.51 $3.84 Million - $5.35 Million	289,090 Added 80.1%	650,000 $11.8 Million
Q4 2018 Feb 14, 2019	SELL	$13.83 - $22.97 $50,465 - $83,817	-3,649 Reduced 1.0%	360,910 $5.8 Million
Q3 2018 Nov 14, 2018	BUY	$20.06 - $26.94 $7.31 Million - $9.82 Million	364,559 New	364,559 $8.75 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.